Blood pressure variability: cardiovascular risk integrator or independent risk factor?

Blood pressure (BP) variability is associated with several cardiovascular (CV) risk factors. Is BP variability measurement of any additive value, in terms of CV risk assessment strategies? To answer this question, we analyzed data from the SU.FOL.OM3 secondary prevention trial that included 2501 patients with background of CV disease history (coronary or cerebrovascular disease). BP was measured every year allowing calculation of variability of BP, expressed as s.d. and coefficient of variability (s.d./mean systolic BP) in 2157 patients. We found that systolic BP variability was associated with several CV risk factors: principally hypertension, age, and diabetes. Furthermore, all antihypertensives were positively associated with variability. Logistic regression analysis revealed that three factors were independent predictors of major CV event: coefficient of variability of systolic BP (OR=1.23 per s.d., 95% CI: 1.04-1.46, P=0.016), current smoking (OR=1.94, 95% CI: 1.03-3.66, P=0.039), and inclusion for cerebrovascular disease (OR=1.92, 95% CI: 1.29-2.87, P=0.001). Finally, when comparing logistic regression models characteristics without, and then with, inclusion of BP variability, there was a modest but statistically significant improvement (P=0.04). In conclusion, age, BP and diabetes were the major determinants of BP variability. Furthermore, BP variability has an independent prognostic value in the prediction of major CV events; but improvement in the prediction model was quite modest. This last finding is more in favor of BP variability acting as an integrator of CV risk than acting as a robust independent CV risk factor in this high-risk population.

[NMR perfusion imaging: applications to the study of brain tumor angiogenesis]. / L'imagerie RMN de perfusion: applications a l'étude de l'angiogenèse tumorale en pathologie cérébrale.

NMR imaging allow specific study of contrast variations due to intravascular agents. It is possible to measure regional cerebral blood volume (rCBV). In brain tumor, this parameter allow to characterize tumoral vascularisation and blood brain barrier lesions. We use today 1st pass bolus technic. Easy to perform in clinical practice, it is useful for differential diagnosis, prebiopsic planning and follow up of lesions. That should be particularly interesting to evaluate the anti-angiogenic treatment efficiency.